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Cocaine addiction is characterized by overwhelming craving for the substance, which drives 
its escalating use despite adverse consequences. Animal models suggest a disrupted 
glutamate homeostasis in the nucleus accumbens to underlie addiction-like behaviour. After 
chronic administration of cocaine, rodents show decreased levels of accumbal glutamate, 
whereas drug-seeking reinstatement is associated with enhanced glutamatergic transmission. 
However, due to technical obstacles, the role of disturbed glutamate homeostasis for cocaine 
addiction in humans remains only partially understood, and accordingly, no approved 
pharmacotherapy exists. Here, we applied a tailored proton magnetic resonance spectroscopy 
protocol that allows glutamate quantification within the human nucleus accumbens. We 
found significantly reduced basal glutamate concentrations in the nucleus accumbens in 
cocaine-addicted (N = 26) compared to healthy individuals (N = 30), and increased glutamate 
levels during cue-induced craving in cocaine-addicted individuals compared to baseline. 
These glutamatergic alterations, however, could not be significantly modulated by a short-
term challenge of N-acetylcysteine (2400 mg/day on two days). Taken together, our findings 
reveal a disturbed accumbal glutamate homeostasis as a key neurometabolic feature of 
cocaine addiction also in humans. Therefore, we suggest the glutamatergic system as a 
promising target for the development of novel pharmacotherapies, and in addition, as a 
potential biomarker for a personalised medicine approach in addiction.  
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Structural and functional adaptations within the neural reward circuitry are at the core of 
cocaine addiction (CA). These alterations promote craving for cocaine, while striving for 
naturally rewarding experiences is blunted 1-4. This dysfunctional reward motivation 
provokes frequent substance taking, and thus can create a vicious circle of addictive 
behaviours. The vulnerability for relapse to substance use is linked to multiple changes in 
reward-relevant neurotransmitter systems, particularly within the nucleus accumbens (Nacc) 
that serves as an integrative hub for translating value representation into action initiation5. 
The current understanding of these alterations underlying addictive behaviours has been 
decisively shaped by insights from animal models. In particular, rodent studies of CA 
identified molecular mechanisms behind drug-seeking behaviour. They indicate destabilising 
consequences of chronic substance administration on glutamate (Glu) homeostasis, especially 
on the balance between synaptic and non-synaptic Glu in the Nacc6,7. Usually, Glu signalling 
is dynamically regulated by astroglial cells which govern its release and uptake8. However, 
these glial regulatory activities are dysfunctional after chronic cocaine administration8, 
leading to decreased basal Glu concentrations in the extrasynaptic space of the Nacc core 
during phases of abstinence6. In turn, relapse-provoking exposure to cocaine challenges or 
conditioned cues result in enhanced stimulation of Glu-ergic transmission9. Given that the 
glial regulation is disrupted, the concentration of synaptically released Glu rises in the Nacc 
core6. Furthermore, this increase in extrasynaptic Glu is associated with amplified substance-
seeking10. 
Gaining a better understanding of the neurobiological adaptations underlying maladaptive 
substance-seeking in humans is necessary for the targeted development of pharmacotherapies 
for CA, which are lacking so far11. Despite the animal model-based understanding of 
substance-related adaptations within the Glu system in the Nacc, sparse evidence exists for 
the translational validity of these models into humans. Extensive efforts have been made to 
capture accumbal Glu homeostasis by applying proton magnetic resonance spectroscopy (1H-
MRS) as a non-invasive technique to determine concentrations of target metabolites such as 
Glu in the brain. However, due to technical challenges of 1H-MRS application, specific 
evaluation of Glu homeostasis within the Nacc of humans with CA has not been achieved 
yet12-15. Conventional 1H-MRS measures yield rather low sensitivity, thus it has been 
challenging to assess the concentration of Glu in the human brain (around 6–12.5 mmol/L) 
that is ~4000–7000 times lower than the corresponding concentration of water16. To 
compensate for the low Glu concentration, larger 1H-MRS acquisition voxels are 
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conventionally required to ensure sufficient signal-to-noise ratio (SNR). However, the size of 
the Nacc (1–2 cm3) requires a small 1H-MRS voxel to assess Glu specifically within this 
region17. Alternatively, to still enable region-specific measurements with sufficient SNR, 
many separate measurements can be assessed and averaged to compensate for the small voxel 
size. However, signal averaging requires a steady measurement environment over time. 
Unfortunately, vessels and ventricles surrounding the Nacc generate pulsating motion and 
magnetic susceptibility changes, which distort MRS line shape and limit the achievable SNR. 
To overcome the addressed issues, we used the water peak with its high SNR as a reference 
for averaging the signals by applying non-water suppressed metabolite cycling 1H-MRS18-20 
to increase the SNR, decrease the linewidth, and thereby enable good spectral quality. 
A further difficulty for neurometablic comparison between clinical and healthy populations in 
general is that metabolic concentrations have previously been evaluated as a relative measure 
only, defined as the ratio of the metabolite of interest to either creatine or water. Since these 
reference molecules could potentially be altered in patients, absolute quantification of 
metabolites of interest is necessary to unambiguously identify pathophysiological shifts of 
metabolites of interest. Therefore, we applied the principle of reciprocity21 to achieve an 
absolute quantification of metabolite concentrations instead of relative measures. 
With this tailored 1H-MRS we first aimed at quantifying accumbal Glu concentrations in 
individuals with cocaine addiction (CAI) and in healthy control individuals (HCI) during 
abstinence to test the glutamate homeostasis hypothesis of addiction in humans. Further, to 
address the potential role of Glu-ergic adaptations during cocaine craving in humans, Glu 
levels were additionally assessed when the desire to use cocaine was provoked with cocaine 
cues. Moreover, we investigated the restoring effect of a N-acetylcysteine challenge (N-
AC)22, that has shown to successfully counterbalance disruptions in Glu homeostasis in 
animal models of addiction23. We expected that CAI would show decreased Glu 
concentrations during abstinence and increased concentrations during craving. For N-AC, we 
hypothesised that it has the potential to normalise Glu and craving levels. 
 
Materials and Methods 
 
Participants 
The study sample consisted of 26 CAI and 30 HCI who were recruited via online and in-house 
advertisement. Inclusion criteria for CAI were a minimum average cocaine use of 1 g per week 
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within the last 6 months and a diagnosis of cocaine dependence according to the Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)24. Exclusion criteria for 
CAI were other DSM-IV axis I psychiatric disorders including dependence of other 
psychoactive substances (excluding tobacco dependence and attention-deficit/hyperactivity 
disorder). Exclusion criteria of HCI were regular use of psychoactive substances with exception 
of current alcohol and irregular cannabis use. Additionally, also DSM-IV axis I psychiatric 
disorders (excluding tobacco dependence) lead to exclusion of HCI. General exclusion criteria 
for all participants were contraindication for magnetic resonance imaging, allergy from N-AC, 
severe somatic diseases, neurological disorders, prior head injury, pregnancy, lack of 
contraception, family history of severe DSM-IV axis I psychiatric disorders, and concurrent 
participation in another clinical trial.  
All participants gave written informed consent in accordance with the declaration of Helsinki 
before study participation and received financial compensation after study completion or 
termination. The study was approved by the Cantonal Ethics Committee of Zurich (KEK ZH 
No.: 2014-0010). 
 
1H-MRS data acquisition and analysis 
1H-MRS measurements were performed on a Philips Achieva 3T whole-body scanner 
equipped with a 32-channel receive-only phased-array head coil (Philips Healthcare, Best, 
The Netherlands). High-resolution anatomical images (1 × 1 × 1 mm3) were acquired using a 
standard T1-weighted 3D turbo field echo sequence. 1H-MRS spectra were obtained by 
means of non-water suppressed Point-RESolved Spectroscopy (PRESS) preceded by a 
metabolite-cycling pulse combined with inner-volume saturation (IVS)19. The PRESS 
localisation sequence was set to a repetition time of 2500 ms, echo time of 32 ms and spectral 
bandwidth of 2000 Hz. The metabolite-cycling technique with application of a shift-sensitive 
asymmetric adiabatic inversion pulse allowed alternately inverting either up- or downfield 
metabolites without affecting the water signal16,18-20. This enables simultaneous analyses of 
the water peak and metabolite signals after separating metabolite peaks from the water peak 
and sideband artefacts by either adding or subtracting consecutively acquired echoes. The 
unsuppressed water peak with its high SNR can be used as a reference for frequency 
alignment, phase and eddy current correction of all individual signals before averaging to 
enable optimal spectral quality. After metabolite-cycling pulses, IVS was implemented to 
enable precise voxel placement, to reduce chemical shift displacement errors between 
metabolites, and to reduce flow artefacts by applying six saturation bands (Fig. 1a; blue) 
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based on highly selective, broadband radiofrequency pulses with polynomial phase response. 
Based on the T1-weighted image, the 1H-MRS voxel (effective size after IVS: 9.4 × 18.8 × 
8.4 mm3) was positioned and tilted to cover the left Nacc. In four blocks of 128 signals a total 
of 512 signals were achieved, which lasted 22.5 minutes. 
For quantification of spectral data, LCModel25 with a set of basis spectra, consisting of 18 
metabolites, was used (Fig. 1b). To account for potential cerebrospinal fluid fraction in the 
measured voxel, the T1-weighted images were segmented using SPM826. Absolute 
quantification of metabolites was performed using an approach exploiting the phantom 
replacement method. To ensure adequate correction of differences between the acquisition of 
the phantom and the in-vivo measurement including corrections for coil loading and B1 
inhomogeneity, the principle of reciprocity was applied as described in more details by 
Zoelch and colleagues21 and in the Supplementary Information. An in-house patch for the 
code of the Philips scanner, allowing for the use of the metabolite cycling technique and the 
absolute quantification method, was used and is available upon request. 
 
Craving paradigm 
During the 1H-MRS measurements, all participants watched two customised films, one as a 
control condition and the other one to provoke the desire to use cocaine. The first film 
showed video clips of a chess game to assess basal Glu levels (neutral film), while the second 
film showed clips of cocaine preparation and consumption to measure craving-induced Glu 
(cocaine film). The film order was not randomised to avoid carry-over effects of cocaine 
craving. These films were specifically created for this study in cooperation with professional 
actors and filmmakers to enable (a) accurate comparison between equivalent experimental 
and neutral condition; in both films, an interaction between two male protagonists is featured 
and both clips incorporate the same objects except for the chessboard and the cocaine 
paraphernalia, respectively. A customised cocaine film further allows (b) to expose 
participants to locally characteristic paraphernalia, and thereby the stimulus overcomes 
cultural diversity in substance use that might otherwise compromise authenticity. These 
authentic visual stimuli were accompanied by auditory stimuli such as the clicking sound of 
the chess pieces or the grinding and sniffing of cocaine to allow an immersive experience. In 
both films, the video clips were interleaved with blank black screens of 2.5 minutes. Before 
film presentations, participants were asked in a written instruction to empathise with the 
scenes shown in the video clips and to recollect similar autobiographic experiences during 
black pauses. 
Impaired glutamate homeostasis… 
 7 
Subjective craving was assessed on a visual analogue scale ranging from 0 to 10 with 
intervals of 0.25 (0 = no craving; 10 = strong craving). Participants rated their craving on this 
scale with a computer mouse while lying in the scanner, directly before and after each film. 
 
Pharmacological challenge 
The pharmacological challenge comprised the cysteine prodrug N-AC that is approved as a 
mucolytic and to treat acetaminophen overdose. A number of animal studies administering N-
AC, which binds to cysteine-glutamate antiporters, were able to regulate Glu synthesis and 
cycling, and thus successfully modulate alterations in the Glu homeostasis after chronic 
cocaine administration. 
The challenge was given as a dose of 2400 mg/day on two consecutive days. The dosage was 
selected based on a study assessing the safety and tolerability of three doses, showing no 
significant difference between 1200, 2400, or 3600 mg/day in terms of side effects27. 
Additionally, preliminary data suggests that the dosage of 2400 mg/day N-AC is potentially 
effective on craving, relapse, and on Glu levels in the cingulate gyrus in addiction23.  
Here, the main goal was to investigate the potential impact of N-AC on the Glu homeostasis 
in the Nacc. The treatment period of two days was therefore chosen to be short enough to 
maximize compliance and to minimize dropouts, yet long enough to see a potential effect 
according to previous reports23. The effect of N-AC was tested against a placebo, in the form 
of identical capsules of mannitol, to enable a randomized, double-blind, placebo-controlled 
and crossover procedure. The first dose of either N-AC or placebo was handed out to our 
participants on their assessment visit. The sequence of N-AC and placebo sessions were 
randomized and counterbalanced to avoid order and sequence effects. Participants were 
instructed to take the first dose one day prior to the first measurement day, 1200 mg in the 
morning and in the evening. On the measurement day itself, the second dose of 2400 mg was 
administered on site one hour prior to the 1H-MRS measurement, since peak plasma 
concentration of N-AC occurs ~1–2 hours after ingestion28. After the first measurement day, 
participants were crossed over to receive the other compound in the same administration 
regimen for the second measurement. Both measurement sessions were performed the same 
way. To ensure complete washout of the compounds, the sessions were separated by an 
interval of 14 days (± 4 days). For more details, see Supplementary Information and 
Supplementary Fig. S1. 
 
Statistical analysis 
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All analyses were performed in a sample consisting of 26 CAI and 30 HCI, unless stated 
otherwise. For detailed description of data exclusion, see Supplementary Information. In 
order to allow the inclusion of all available data from every subject despite missing of single 
measurements, a multilevel approach was applied. Uneven data sets and irregular time 
intervals between measurement points were taken into account28, since random coefficients 
allow modelling the time course as continuous variable based on the assumption that slopes 
and intercepts vary randomly across individuals29. The random coefficient model estimated 
the impact of cocaine addiction (Table 1; CAI) and cocaine-cue stimulation (Table 1; cocaine 
film) as fixed effects on either the dependent variable Glu or craving to investigate their 
differences between groups and conditions (Figs. 2 and 3, respectively). The same model was 
estimated for Glx. We included time, age, sex, and duration of abstinence (analysis of urine 
samples and log-transformed hours since last cocaine use prior to measurement) as predicting 
variables in our multilevel models. None of these variables had an influence on Glu and 
craving levels before and after stimulation with the cocaine film, and were therefore omitted 
from the final models. All random coefficient models were fitted using SAS V9.4 with the 
function proc mixed following Brown and Prescott29 or proc nlmixed when accounting for 
variance inhomogeneity. Variance was observed to be inhomogeneous for craving as 
dependent variable. As the results did not differ substantially, only the model assuming 
variance homogeneity between groups is presented. Examination of possible outliers, test for 
normal distribution, and all other statistical calculations were performed with SPSS 25.0. 
Since guidelines regarding effect sizes for multilevel models have not yet been established, 
we calculated effect sizes using Cohen’s d for group differences of main interest taking into 




Demographic characteristics and cocaine consumption 
The groups were matched regarding age, sex, education, verbal intelligence, and smoking 
status. In CAI, mean cocaine consumption rate and dose within the last six months was 3.40 
times per week (± 1.89 s.d., range: 0.46 - 7) and 5.52 grams per week (± 10.03 s.d., range: 1 - 
52.50). The main route of cocaine administration was intranasal (22 CAI), while 4 CAI were 
primarily inhaling cocaine. For full characterization of the final sample regarding 
demographics, matching and substance use, see Supplementary Table S1 and S2. 
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Craving induction 
Overall, CAI showed substantially higher craving ratings than HCI (P < 0.0001, d = 1.67, 
95% CI [1.06, 2.28], d calculated for pre neutral film HCI vs. CAI). Craving ratings increased 
strongly after presentation of the cocaine film only among CAI (P = 0.0002, d = 0.85, 95% 
CI [0.28, 1.42]), while HCI did not report any cocaine craving (Fig. 2). 
 
1H-MRS quality 
According to general MRS quality criteria from the MR Spectroscopy Consensus Group30, 
the upper limit for linewidth (full-width at half-maximum peak height) was defined as < 12.7 
Hz (0.1 ppm)30. The threshold for sufficient SNR was set > 10. Based on this quality 
assessment, five measurements were excluded from analysis (for details see Supplementary 
Information). In the resulting data set, Cramér-Rao Lower Bounds (CRLB) for Glu were ≤ 
11% for all measurements. CRLB serve as quality criterion to determine the reliability of the 
fit for each metabolite and are considered reliable when < 20%30. 
For exemplary spectrum and overall MRS data quality see Fig. 1 and Supplementary Table 
S3. All parameters for spectral quality are further presented per condition in the 
Supplementary Tables S4 – S7. Spectral quality between groups in the four different 
conditions did not differ (P > 0.2), thus enabled valid group comparisons between conditions 
(for statistics see Supplementary Tables S4 – S7). 
 
Glutamate concentration in the Nacc 
We found strongly decreased basal Glu concentrations in CAI (P = 0.0047, d = -0.89, 95% CI 
[-1.47, -0.32]) compared to HCI during the neutral film (Table 1 and Fig. 3). In accordance 
with the described raise of craving level in CAI, we also observed elevated Glu 
concentrations in the Nacc of CAI during the cocaine film. An interaction effect showed an 
increase in Glu levels from the neutral to the cocaine film in CAI, while in HCI a reduction 
was observed (P = 0.013 dCAI = 0.44, 95% CI [-0.12, 1.00], dHCI = -0.50, 95% CI [-1.03, 
0.02], Table 1 and Fig. 3). Also for Glx, a significant main effect of film was found, while 
trends were observed for the group and the interaction effect (for details see Supplementary 
Table S8). There was no significant correlation between Glu and craving levels in the cocaine 
film condition (P > 0.35). 
 
Pharmacological modulation 
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Contrary to expectations, the pharmacological challenge showed neither an effect on craving 
nor on Glu levels in CAI. However, the cue-induced Glu increase in CAI while taking 
placebo (see Table 1 and Fig. 3) was no longer observed in the N-AC condition. 
Unexpectedly, the N-AC challenge showed a strong effect on Glu in HCI (P = 0.024, d = -
0.82, 95% CI [-1.36, -0.28], d calculated for neutral film placebo vs. N-AC), contrary to the 
expected effect on CAI, leading to an overall reduction in Glu across both conditions 
(Supplementary Table S9). For an overview of adverse events during study duration, see 
Supplementary Table S10. 
 
Discussion 
Research focussing on the role of the dopamine system in addiction has significantly 
advanced our understanding of the disease, whereas it has not resulted in effective treatments 
yet (26). Here, we evaluated alterations in the Glu-ergic homeostasis in the Nacc in CAI, 
since animal models suggested Glu imbalance in the Nacc to underlie addiction-like 
behaviour6. Therefore, we examined Glu concentrations in the Nacc of CAI by means of a 
dedicated 1H-MRS protocol. In accordance with animal models of addiction6, our data 
provide the first evidence in humans that CA is characterized by profound Glu-ergic shifts 
within the Nacc. We show that Glu concentrations in the Nacc were reduced in CAI in the 
withdrawal state relative to HCI, whereas Glu levels in CAI were amplified by visual and 
auditory cocaine-related cues reliably inducing craving symptoms. These results are 
consistent with alterations in Glu transmission described in substance-seeking reinstatement 
models in rodents, and indicate that accumbal Glu signalling is generally inhibited after 
chronic cocaine use and is accelerated during cue-exposure. This Glu imbalance is in line 
with, and might be explained by, molecular mechanisms that have been observed in animals 
exposed to cocaine. After withdrawal from cocaine, the expression of Glu transporters 1 and 
regulation via glial glutamate-cystine transporters are consistently down-regulated9,31-33. As 
extracellular Glu normally provides release-regulating tone on presynaptic metabotropic Glu 
receptors 2 and 3 (mGluR2/3)34, the signalling of mGluR2/3 is diminished following chronic 
cocaine administration9,35. Together, these adaptations in the Glu system lead to decreased 
basal Glu concentration in the extrasynaptic space of the Nacc core after chronic cocaine 
administration. In turn, during substance-seeking reinstatement, dysregulated Glu release 
combined with impaired Glu removal promotes an overflow of synaptically released Glu in 
the Nacc core9. Thus, our findings might reflect a common Glu-ergic dysfunction in the Nacc 
underlying the mammalian craving brain. 
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However, 1H-MRS does not allow differentiating intra- and extrasynaptic Glu, and therefore 
final inferences from Glu concentrations regarding directional Glu distribution within the 
different cellular compartments in humans are not possible yet. Spatial inferences are further 
restricted since voxel size and shape, which define the region wherein Glu is measured by 1H-
MRS, cover the Nacc including both core and shell regions, whereas preclinical findings 
described Glu changes within the core only. On the contrary, this limited spatial specificity 
rather amplifies the probability for false negative results, not for false positives. 
Given that the Nacc has been suggested to be also involved in salience detection36 as well as 
in sleep-wake homeostasis37, the present Glu decrease observed in HCI while watching the 
cocaine film might reflect a decrease of salience of the audio-visual inputs over time together 
with a fatigue-driven Glu reduction, since the cocaine film was always shown after the 
neutral film and might constitute a stimulus with low salience for HCI. In CAI, on the other 
hand, the expected higher salience of cocaine-related cues38 together with heightened arousal 
might contribute to increased Glu levels during the cocaine film, analogue to animals 
showing accelerated Glu release in the Nacc in response to cues linked with incentive 
salience39. 
Glu imbalance in CAI was not significantly modulated by the short-term intake of N-AC 
(Table 1). However, in the N-AC condition, the cue-induced Glu increase in CAI while 
taking placebo was no longer observed, whereas N-AC had no impact on craving ratings. 
Given that N-AC caused a significant reduction of Glu in the control group, which is in line 
with recent 1H-MRS Glu measures of the basal ganglia in a healthy population40, N-AC 
seems, in principle, capable of affecting the Glu system of the human brain. Further, recent 
findings have shown beneficial effects of long-term N-AC interventions of 25 days (as 
compared to our two-day administration) on problems related to CA41. Thus, an adjustment 
of the duration and potentially of the dose of N-AC intervention might be needed for 
reducing craving in CAI. Lastly, since the mechanisms of N-AC are far from being fully 
understood42, it remains challenging to interpret our unanticipated findings regarding the N-
AC administration. Thus, the impact of numerous other pharmacological compounds 
targeting the Glu system43 should be further studied by means of a small-voxel 1H-MRS 
approach as proposed here. We hypothesise that Glu levels within the human Nacc could 
serve as a non-invasive biomarker to predict individual treatment responses in future clinical 
trials. Namely, such a biomarker would allow identifying individuals who benefit the most 
from pharmacological interventions aiming at restoring disturbances within the Glu 
homeostasis in CAI, and thus would enable a personalized pharmacological treatment. 
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In sum, our findings contribute to the establishment of a translational framework of 
neurometabolic changes within the Glu system underlying CA across species that will 
enhance our understanding of addictive disorders, and, most importantly can thereby foster 
the development of urgently needed novel pharmacotherapies that target the Glu system. 
 
Supplementary Information accompanies the paper on the Molecular Psychiatry’s website 
(http://www.nature.com/mp).  
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Figure 1. Proton magnetic resonance spectroscopy (1H-MRS) assessment of glutamate 
concentration in the nucleus accumbens. (A) Coronal, sagittal and axial slice of T1-weighted 
images of the brain illustrating the tilted position of the 1H-MRS acquisition voxel centred on 
the left nucleus accumbens. The effective voxel size (white; 9.4 × 18.8 × 8.4 mm3) results 
from the overlap localized volumes of lactate/lipid (black) and water (green) defined by 
saturation bands (blue; for details see Supplementary Information). The shim box is indicated 
in orange. (B) Exemplary single spectrum measured therein (black), LCModel fit (red), fit-
residuals (above; black), and glutamate and glutamine extracted (yellow).  




Figure 2. Craving as a function of cocaine-cue stimulation. Plot of mean craving ratings per 
group before and after the presentation of a neutral and a cocaine film represented as dots 
with standard error bars; blue = healthy control individuals, red = cocaine-addicted 
individuals. A: Placebo condition: A random coefficient model showed significantly higher 
craving ratings in cocaine-addicted individuals (P < 0.0001, N = 26) at all measurement 
points compared to healthy control individuals (N = 30), and significantly increased craving 
ratings after the cocaine film in cocaine-addicted individuals compared to their ratings before 
the cocaine film (P = 0.0002). B: N-acetylcysteine (N-AC) condition: No significant effects 
were observed for either group. For statistics, see Table 1.  




Figure 3. Impact of cocaine-cue stimulation on glutamate levels within the nucleus 
accumbens in cocaine addiction. Plot of mean glutamate concentrations in millimoles per litre 
(mmol/L) per group during presentation of a neutral and a cocaine film represented as dots 
with standard error bars; blue = healthy control individuals, red = cocaine-addicted 
individuals. A: Placebo condition: A random coefficient model showed significantly lower 
basal glutamate levels (neutral film, P = 0.0047) in cocaine-addicted individuals (N = 26) 
compared to healthy control individuals (N = 30), and significantly increased cue-induced 
glutamate levels (cocaine film) compared to baseline levels (neutral film, P = 0.013). B: N-
acetylcysteine (N-AC) condition: No significant effect was observed in cocaine-addicted 
individuals, while a significant main effect for N-AC was found for healthy control 
individuals. For statistics, see Table 1.  
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Table 1. Random coefficients model for craving and for glutamate measures 
 Dependent variables 
 Craving levels Glutamate ratings 
Fixed effects estimate ± s.e.m. P Value estimate ± s.e.m. P Value 
 Intercept (HCI)        0.03 ± 0.34    0.92      12.62 ± 0.35 < 0.0001**** 
 CAI (vs. HCI)        3.02 ± 0.50 < 0.0001****       -1.51 ± 0.51    0.0047** 
 Cocaine film       -0.02 ± 0.28    0.95       -0.91 ± 0.46    0.053 
 CAI  cocaine 
film 
       1.69 ± 0.41    0.0002***        1.72 ± 0.67    0.013* 
     
Residual 1.12  2.95  
Number of parameters 5  5  
     
Number of participants 56 (26 CAI/30 HCI) 56 (26 CAI/30 HCI) 
Number of data points  108   107  
 
Table 1. Group differences and influence of cocaine film displayed by estimates and 
standard errors (s.e.m.) for main effects (CAI, cocaine film) in reference to HCI (intercept), 
and by the interaction term (CAI x cocaine film). 
CAI = cocaine-addicted individuals 
HCI = healthy control individuals  
* P < .05; ** P < .01; *** P < .001 **** P < 0.0001 
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The initial definition of sample size N = 30/30 resulted from a power analysis (80% power, d 
= 0.8, P < 0.5) based on previous 1H-MRS measures of glutamate (Glu) in prefrontal areas of 
cocaine users (Hulka, 2014), and an anticipated dropout rate of 30%. Since data loss was higher 
than anticipated, 36 cocaine-addicted individuals (CAI) and 33 healthy control individuals 
(HCI) were randomised into the study (03.2015 – 04.2016). In 40.6% (CAI: 17; HCI: 10) of 
all participants at least one of four data sets were missing, and of 23.2% (CAI: 12; HCI: 4) of 
all participants the complete data set was missing or could not be used. 
Two CAI aborted the study participation due to unexpected sensation of claustrophobia when 
entering the magnetic resonance scanner. Four participants (three HCI; one CAI) aborted the 
study participation during or after the first proton magnetic resonance spectroscopy (1H-MRS) 
session because of demotivation, two participants (one HCI; one CAI) citing scheduling 
difficulties, two participants (one HCI; one CAI) because of acute illness and one HCI due to 
discomfort in the magnetic resonance scanner (neck pain). Two CAI did not attend their study 
sessions for unknown reasons. Further, two CAI began novel pharmacological treatments 
(methylphenidate) during the study participation, either prior to the first or to the second 1H-
MRS session. The hair analysis of one CAI revealed a mean cocaine concentration during the 
last six months slightly below the threshold of reliable detection (< 500 mg/mg). This clearly 
indicates a merely occasional cocaine use at most, thus, likely below the predefined minimum 
of one gram per week. Further, the hair analysis of one HCI unveiled concealed 
pharmacological treatment for epilepsy targeting the GABA and Glu system and was therefore 
excluded. Two CAI and one HCI were sleeping during the 1H-MRS measurement and were 
therefore excluded. Two 1H-MRS measurements were excluded owing to subject motion of > 
5 mm, two measurements due to SNR ≤ 10 and one measurement due to linewidth > 12.7 Hz. 
In total, five 1H-MRS measurements were excluded based on poor data quality (two HCI; three 
CAI). Finally, two CAI and one HCI could not be measured at the second session as of technical 
issues with the magnetic resonance scanner. 
After all affected measurements were excluded, data from 26 CAI and 30 HCI were included 
in the analysis, unless stated otherwise. The participants with adequate 1H-MRS data acquired 
in the placebo condition served as a reference for the sample selection for all other analysis. 
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Sample characteristics 
As expected and in line with previous studies1,2, CAI reported significantly more symptoms in 
the Beck Depression Inventory (BDI)3 and the attention-deficit hyperactivity disorder (ADHD) 
self-rating scale (ADHD-SR)4, and scored higher on the Fagerström Test for Nicotine 





This study was designed as a randomized, double-blind, placebo-controlled, crossover trial 
(clinicalTrial.gov identifier: NCT02626494). The complete investigation consisted of three 
measurement time points and was conducted at the Psychiatric Hospital of the University of 
Zurich (for illustration of study design and participant allocation see Figure S1). The first 
measurement session was conducted to examine demographic data, psychiatric disorders, 
substance use, and personality traits. Psychologists screened all participants for the presence 
of DSM-IV axis I psychiatric disorders using the Mini-International Neuropsychiatric 
Interview6 as a structured diagnostic psychiatric interview. Substance use was assessed by 
means of a structured and standardized Interview for Psychotropic Drug Consumption7, and 
hair samples were collected to objectively characterize substance use over the past three to 
six months. 
To match the two groups, demographic information and smoking habits were collected with 
a computer-based questionnaire. Additionally, the Mehrfachwahl Wortschatz Intelligenztest 
(MWT-B) was applied to capture premorbid verbal intelligence8. For further characterisation 
of the sample, all participants completed standardized questionnaires concerning individual 
traits. The BDI3 and the ADHD-SR4 measured current symptoms of depression and ADHD, 
respectively. The Barratt Impulsiveness Scale (BIS-11)9 was applied to estimate trait 
impulsivity. The Fagerström Test for Nicotine Dependence (FST)5 was used to determine 
severity of nicotine dependence, and the Alcohol Use Disorder Identification Test (AUDIT)10 
to assess the risk for alcohol abuse. 
After the assessment session, two identical 1H-MRS measurement sessions on two separate 
days followed to allow placebo-controlled investigation of a short-term N-acetylcysteine (N-
AC) challenge. Both 1H-MRS sessions started in the morning. According to the procedures in 
preclinical studies, all participants were asked to refrain from illicit substances for three days, 
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from alcohol for two days, and usual tobacco consumption was allowed until one hour prior 
to the 1H-MRS scans.  
 
1H-MRS data acquisition 
Prior to each of four blocks of a scan, all preparation steps, including power optimization, 
centre frequency, shimming, receiver gain optimization, were repeatedly carried out to take 
potential scanner drifts into account. After each block, voxel position was revised by 
acquiring an axial T2-weighted image, since even small participant movements lead to 
incorrect positions for small voxels. If a change of voxel position (> 5 mm) was detected and 
if the experimental time schedule allowed it, the voxel placement was repositioned for the 
next block. This block replaced the previous block affected by participant movement. If 
repetition of the block was not possible, spectra with subject motion > 5 mm were excluded 
from analysis.  
Further, to avoid estimations of the water concentration and relaxation properties in the 
investigated tissue, a calibration strategy based on a reference signal acquired in a phantom 
with known concentrations was applied. Necessary corrections for sensitivity and coil loading 
changes between in-vivo and phantom measurement were performed11. In this approach, the 
optimal radiofrequency pulse voltage, as a measure of coil sensitivity and coil loading, is 
automatically determined by using the selective power optimization12 prior to each 
measurement. After correction, external referencing allows estimation of absolute 
concentrations of metabolites. Additional corrections for potential deviations of the transmit 
sensitivity from the receptions sensitivity11 were omitted due to the small distance between 
voxel position and the central axis of the coil. Segmentation of T1-weighted images within 
acquisition voxel using SPM813 revealed mean tissue composition of grey matter (~77%), 
white matter (~23%) and cerebrospinal fluid (0%) did not differ between groups (NCAI = 95, 
NHCI = 110, independent t-test, 2-tailed, P > 0.6,). Given that there was no cerebrospinal fluid 
fraction within the voxel, it appears that the applied small voxel allowed an unprecedented 
precise assessment of the Nacc. 
 
1H-MRS quality 
Table S3 presents the achieved 1H-MRS data quality across groups and over all conditions after 
exclusion of six measurements due to poor quality as described in detail in Sample size. To test 
whether there are differences in spectral quality between groups, we compared the 1H-MRS 
quality parameters of each condition between the groups. All parameters were comparable as 
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shown in Table S4 – S7. Further to ensure, that the within-group Glu difference in CAI between 
neutral and cocaine film did not result from quality inequalities, a post-hock ANOVA was 
performed. The results show that 1H-MRS quality parameters of CAI did not differ between 
the films in the placebo condition (N = 24/26, one-way ANOVA, P > 0.2). 
Glu is synthesised by glutamine and their chemical similarity leads to overlapping magnetic 
resonance spectra14, which impedes unambiguous independent quantification of Glu and 
glutamine at field strength < 7 Tesla. To date, this impediment has not been fully overcome, 
and thus remains a challenge of in vivo Glu quantification. Nonetheless, we strived to address 
this issue by tailoring a dedicated 1H-MRS protocol for low concentrated metabolites and small 
brain regions. We performed further a diligent quality assessment of the achieved data 
following consensus guidelines15, which were clearly fulfilled despite size and localisation of 
the applied voxel. Moreover, these considerations apply to both CAI and HCI to the same 
extent, therefore enabling a valid comparison between groups. Finally, the achieved results 
coincide with our apriori hypotheses, and thus with the well-studied animal model. 
 
Pharmacological challenge 
The use of N-AC was authorized by Swissmedic, the Swiss agency for therapeutic products. 
The study compounds were manufactured, randomised and blinded by the cantonal pharmacy 
of Zurich following Good Clinical Practice guidelines. Block randomisation of the study 
compound was implemented for the verum-placebo sequence to ensure a balance of the 
challenge order within groups. Forty study compounds for each group were prepared by the 
cantonal pharmacy of Zurich in sequentially numbered containers. During the study duration, 
both participants and investigators were blinded for the sequence allocation. It remained 
concealed until the last visit of the last patient was completed and was then revealed to the 
investigators by the cantonal pharmacy of Zurich for data analysis. 
To increase the compliance of participants, they received a personalised study schedule, a 
medication study diary and a reminder by a study investigator. At the beginning of every 
visit, participants were casually asked about their well-being. During the entire study 
duration, no severe and no unexpected adverse events were reported. All adverse events were 
mild to moderate and contained previously described side effects, mainly on the 
gastrointestinal system. Overall, two participants (3.57 %) reported adverse events in the 
placebo condition, while five participants (9.26 %) reported adverse events in the N-AC 
condition. A detailed overview of adverse events is given in the Table S10. 
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Urine screening and hair analysis 
Adherence with instructions regarding abstinence of psychoactive substances was monitored 
by qualitative urine analyses. Urine samples of 12 and 13 CAI, respectively, were positive for 
cocaine at the 1H-MRS sessions in the placebo and the N-AC condition (for details, see Table 
S2). Since metabolites of psychoactive substances can be detectable in urine for more than 
three days in regular users, we included those participants with positive screening results into 
the analyses and controlled for its effect on Glu and craving. All urine samples of HCI were 
negative. 
Quantification of the consumption of psychoactive substances over the past three and up to 
six months (depending on hair length) was performed by hair toxicology analyses. Proximal 
hair segments were analysed with liquid chromatography-tandem mass spectrometry based 
on a method by Rust and colleagues16. Overall, results confirmed regular use of cocaine and 
clear dominance of cocaine in CAI over other psychoactive substances (for details, see Table 
S2). Two hair analyses lead to data exclusion, for details see Sample size.  
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Figure S1. Illustration of study design and participant allocation. The study was performed in 
a randomized placebo-controlled double-blind cross-over design. a) After the assessment of 
eligibility criteria, participants were randomly assigned to an intervention order. b) The first 
proton magnetic resonance spectroscopy (1H-MRS) was performed under either placebo or 
verum (N-acetylcysteine). To rule out potential carry-over effects, a wash-out period of 14 
days (± 4 days) followed the first 1H-MRS session/compound intake. c) The 1H-MRS session 
was repeated and the other compound was administered. Allocation ratios per conditions are 
indicated over all participants and separately for the groups. 
CAI = Cocaine-addicted individuals 
HCI = Healthy control individuals  
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  Table S1. Description and comparison of demographic data within and between groups   
    Healthy control individuals Cocaine-addicted individuals         
        Value df P Value   
  Male/female  19/11 19/7 2 =  0.61 1 0.436   
  Age in years 29.50 ± 5.76   29.94 ± 5.99   t =  0.28  54 0.785   
  Years of education 10.02 ± 1.42    9.85 ± 2.49   t = -0.32 54 0.750   
  Verbal IQ ° 105.38 ± 12.06 101.15 ± 9.91   t = -1.29 47 0.202   
  Smoker/non-smoker 23/7 24/2 FET  0.109   
  FTND sum score (0-10)    1.30 ± 1.97    3.85 ± 2.72   t =  4.05 54 0.0002***   
  AUDIT sum score (0-32)    4.80 ± 2.80  10.54 ± 6.72   t =  4.28 54 0.00008****   
  ADHD-SR sum score (0-54)    8.50 ± 6.32  13.54 ± 8.85   t =  2.48 54 0.017*   
  BDI sum score (0-63)    3.10 ± 3.39    7.62 ± 7.82   t =  2.87 54 0.006**   
 
 
Table S1. Means ± standard deviations of demographic data per group. Groups were matched 
on age, sex, verbal intelligence quotient (IQ) and smoking status. Sample size N for cocaine-
addicted individuals (CAI) and healthy control individuals (HCI), unless stated otherwise: 
NCAI = 26 NHCI = 30. 
° Verbal IQ was assessed with a test only applicable in German native speaking participants: 
NCAI = 20 NHCI = 29 
FTND: Fagerström Test of Nicotine Dependence 
ADHD-SR: Attention-Deficit/Hyperactivity Disorder Self-Rating Scale 
BDI: Beck Depression Inventory 
2: 2-test for frequency data 
t: independent t-test 
FEZ: Fisher's exact test one-sided. 
* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001  
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Table S2. Means ± standard deviations (s.d.) of substance use per group. Substance use in 
grams per week and frequency per week were based on self-report and averaged over the last 
six months. For self-report measures, sample size for healthy control individuals (HCI) and 
for cocaine-addicted individuals (CAI), unless otherwise stated: NCAI = 26 NHCI = 30. Hair 
toxicology was analysed in two samples of total 6 cm, if available. The average of the two 
samples captured substance use over the last six months. If the hair sample was shorter than 6 
  Table S2. Description and comparison of psychoactive substance use within and between groups   




individuals         
    mean ± s.d. Value df P Value   
  Cocaine         
   Grams/week   5.52 ± 10.03 0 tW = 2.81 25    0.010*   
   Frequency/week°  3.40 ± 1.90 0 tW = 9.00 24 < 0.0001****   
   Cumulative dose (grams/lifetime) 1782.56 ± 2378.46 0 tW = 3.82 25    0.0008***   
   Years of use 6.31 ± 4.01 0 tW = 8.02 25 < 0.0001****   
   Urine toxicology (pos/neg) P: 12/14   V: 13/13 t1: 0/30    t2: 0/30 - -        -   
   Hair toxicology (pg/mg)a 20377.80 ± 23006.14 0 tW = 4.25 22 < 0.0001   
  Alcohol        
   Grams/week 276.66 ± 540.01 58.54 ± 52.59 tW = 2.05 25.4    0.051   
  Nicotine        
   Cigarettes/week 95.54 ± 68.67 46.16 ± 44.57 tW = 3.14 41.8    0.003**   
  Cannabis        
   Grams/week°  2.42 ± 6.42 0.02 ± 0.04 tW = 1.88 24    0.073   
   Urine toxicology (pos/neg) P: 6/20   V: 7/19 t1: 0/30    t2: 0/30 - -        -   
  Amphetamine        
   Grams/week 0.15 ± 0.54 0 tW = 1.38 25    0.179   
   Urine toxicology (pos/neg) P: 1/25   V: 0/26 t1: 0/30    t2: 0/30 - -        -   
   Hair toxicology amphetamine (pg/mg)b   650.00 ± 1149.13 0 tW = 2.71 22    0.013*   
   Hair toxicology methamphetamine (pg/mg)c   392.39 ± 1811.77 0 tW = 1.04 22    0.310   
  MDMA         
   Milligrams/week°  20.83 ± 40.77 0.64 ± 2.87 tW = 2.47 24.2    0.021*   
   Hair toxicology MDMA (pg/mg)d 1779.67 ± 3164.51   39.14 ± 206.01 tW = 2.63 22.2    0.015*   
  Opioid        
   Grams/week 0.01 ± 0.05 0 tW = 1.43 25    0.165   
   Urine toxicology (pos/neg) P: 0/26   V: 0/26 t1: 0/30    t2: 0/30 - -        -   
   Hair toxicology morphine (pg/mg) 120.00 ± 84.85 0  tW = 1.28 22    0.213   
  GHB        
   Millilitres/week 0.01 ± 0.03 0    tW = 1 25    0.327   
  Hallucinogens        
   Trips/week 0.16 ± 0.59 0 tW = 1.34 25    0.191   
  Ketamine        
   Grams/week 0.02 ± 0.06 0 tW = 1.64 25    0.113   
   Hair toxicology (pg/mg)   756.63 ± 2328.42 0 tW = 1.56 22    0.133   
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cm, only one sample for a shorter time period was analysed. Hair samples of four participants 
were missing due to boldness or dropout: NCAI = 23 NHCI = 29. 
° Due to missing data in one self-report: NCAI = 25 NHCI = 30 
a Sum of cocaine + cocaethylene + norcocaine, Cut-off value for cocaine = 500pg/mg 
b Cut-off value for amphetamine = 200pg/mg 
c Cut-off value for methamphetamine = 200pg/mg 
d Cut-off value for MDMA  = 200pg/mg 
P: placebo, V: verum 
MDMA: 3,4-methylenedioxymethamphetamine 
GHB: gamma-Hydroxybutyric acid 
t: independent t-test for equal variances, 2-tailed 
tW: Welch-test for unequal variances, 2-tailed 
* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001  
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Table S3. Spectral quality over all groups and conditions 
  Mean ± s.d. Minimum Maximum 
SNR 17.46 ± 2.53 11.00 24.00 
Linewidth (Hz)  6.87 ± 1.23 4.34 11.75 
CRLBGlu   (%)  5.07 ± 1.24 3.00 11.00 
 
 
Table S3. Data represent means ± standard deviations (s.d.) of all proton magnetic resonance 
spectroscopy (1H-MRS) measurements (205) across conditions (neutral vs. cocaine film and 
placebo vs. N-acetylcysteine) and groups (healthy control individuals vs. cocaine-addicted 
individuals). To describe the spectral quality assessed, we report signal-to-noise ratio (SNR) 
based on LCModel fittings, water linewidth (full-width at half-maximum peak height), and 
Cramér-Rao Lower Bounds (CRLBs) of the fit of glutamate.  
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 Mean ± s.d. Mean ± s.d. t-Value° df P Value 
Placebo      
 Neutral filma 17.42 ± 2.55 17.39 ± 2.62 -0.033 50 0.97 
 Cocaine filmb 17.19 ± 2.19 17.31 ± 2.75 0.175 53 0.86 
      
Verum      
 Neutral filmc 18.13 ± 2.80 17.65 ± 2.35 -0.648 47 0.52 
 Cocaine filmd 17.59 ± 2.61 17.15 ± 2.52 -0.601 47 0.55 
 
 
Table S4. Sample size N for cocaine-addicted individuals (CAI) and healthy control 
individuals (HCI) differed per condition: 
a NCAI = 24 NHCI = 28 
b NCAI = 26 NHCI = 29 
c NCAI = 23 NHCI = 26 
d NCAI = 22 NHCI = 27 
° Independent t-test, 2-tailed  
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 Mean ± s.d. Mean ± s.d. t-Value° df P Value 
Placebo      
 Neutral filma 6.92 ± 1.30 6.75 ± 1.33 -0.483 50 0.63 
 Cocaine filmb 6.68 ± 0.92 6.85 ± 1.14 0.628 53 0.53 
      
Verum      
 Neutral filmc 6.67 ± 1.14 7.10 ± 1.33 1.219 47 0.23 
 Cocaine filmd 6.92 ± 1.28 7.09 ± 1.39 0.455 47 0.65 
 
Table S5. Sample size N for cocaine-addicted individuals (CAI) and healthy control 
individuals (HCI) differed per condition: 
a NCAI = 24 NHCI = 28 
b NCAI = 26 NHCI = 29 
c NCAI = 23 NHCI = 26 
d NCAI = 22 NHCI = 27 
° Independent t-test, 2-tailed  
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 Mean ± s.d. Mean ± s.d. t-Value° df P Value 
Placebo      
 Neutral filma 5.00 ± 1.10 4.89 ± 0.99 -0.368 50 0.71 
 Cocaine filmb 4.92 ± 1.16 4.97 ± 1.05  0.142 53 0.89 
      
Verum      
 Neutral filmc 5.09 ± 1.44 5.35 ± 1.79  0.554 47 0.58 
 Cocaine filmd 5.23 ± 1.45 5.19 ± 0.83 -0.128 47 0.90 
 
Table S6. Sample size N for cocaine-addicted individuals (CAI) and healthy control 
individuals (HCI) differed per condition: 
a NCAI = 24 NHCI = 28 
b NCAI = 26 NHCI = 29 
c NCAI = 23 NHCI = 26 
d NCAI = 22 NHCI = 27 
° Independent t-test, 2-tailed  
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 Mean ± s.d. Mean ± s.d. t-Value° df P Value 
Placebo      
 Neutral filma 4.46 ± 0.72 4.64 ± 0.91 0.800 50 0.43 
 Cocaine filmb 4.54 ± 0.76 4.66 ± 0.97 0.491 53 0.63 
      
Verum      
 Neutral filmc 4.35 ± 0.65 4.38 ± 0.64 0.200 47 0.84 
 Cocaine filmd 4.59 ± 0.85 4.74 ± 0.71 0.670 47 0.51 
 
 
Table S7. Sample size N for cocaine-addicted individuals (CAI) and healthy control 
individuals (HCI) differed per condition: 
a NCAI = 24 NHCI = 28 
b NCAI = 26 NHCI = 29 
c NCAI = 23 NHCI = 26 
d NCAI = 22 NHCI = 27 
° Independent t-test, 2-tailed  
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Table S8. Random coefficients model for combined glutamate 
+ glutamine levels 
 Dependent variable 
 
Glutamate + glutamine (Glx) 
Fixed effects estimate ± s.e.m. P Value 
 Intercept (HCI)      16.44 ± 0.48 < 0.0001*** 
 CAI (versus HCI)       -1.37 ± 0.70    0.056 
 Cocaine film       -1.28 ± 0.52    0.018* 
 CAI  cocaine film        1.44 ± 0.76    0.066 
   
Residual 3.80  
Number of parameters 5  
   
Number of participants  56  
Number of data points  107  
 
Table S8. Estimates and standard errors (s.e.m.) for main effects (CAI, cocaine film) in 
reference to HCI as intercept, and interaction effect (CAI x cocaine film). 
CAI = cocaine-addicted individuals 
HCI = healthy control individuals 
* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001  
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Table S9. Random coefficient model for glutamate with N-acetylcysteine 
 Dependent variable 
 Glutamate 
 Fixed effects    estimate ±  s.e.m P Value 
 Intercept (CAI) 11.10 ± 0.42         < .0001**** 
 HCI (versus CAI)    1.48 ± 0.58    0.011* 
 Cocaine film   0.83 ± 0.55 0.14 
 HCI  cocaine film  -1.65 ± 0.75    0.030* 
 N-AC   0.23 ± 0.57 0.69 
 HCI  N-AC  -1.78 ± 0.77    0.024* 
 Cocaine film  N-AC  -1.16 ± 0.80 0.15 
 HCI  cocaine film  N-AC    2.19 ± 1.09    0.047* 
   
Residual 3.77  
Number of parameters 9  
   
Number of participants 56  
Number of data points 205  
 
Table S9. Estimates and standard errors (s.e.m.) for main effects (HCI, cocaine film, N-AC) 
in reference to CAI (intercept), and interaction effects. 
CAI = cocaine-addicted individuals 
HCI = healthy control individuals 
N-AC = N-acetylcysteine 
* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001  
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 Table S10. Adverse events during N-acetylcysteine or mannitol challenge  
  Adverse events  
 Challenge reaction severity causality  
 
 Mannitol diarrhoea mild probable 
 
 
 neck pain moderate unlikely 
 
      
 
 N-AC nausea mild probable 
 
 
 local allergic reaction mild unlikely 
 
 
 herpes labialis mild unlikely 
 
 
 transpiration mild possible 
 
 
 Headache, vomitus moderate possible 
 
 
Table S10. Overview of all adverse events that were reported during study participation with 
a two-day challenge of 2400 mg/day N-acetylcysteine (N-AC, verum) and of mannitol 
(placebo). Within the included sample, for intake of verum N = 53, for intake of placebo N = 
56. Among all subjects, there were no serious adverse events observed, and severity of most 
events was rated as mild and two events as moderate. Causality between adverse events and 
the challenge were assessed either as certain, probable, possible or unlikely. 
